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Model of outcomes of screening mammography: information to
support informed choices
Alexandra Barratt, Kirsten Howard, Les Irwig, Glenn Salkeld, Nehmat Houssami
Abstract
Objective To provide easy to use estimates of the benefits and
harms of biennial screening mammography for women aged
40, 50, 60, and 70 years.
Design Markov process model, with data from BreastScreen
Australia, the Australian Institute of Health and Welfare, and
the Australian Bureau of Statistics.
Main outcome measure Age specific outcomes expressed per
1000 women over 10 years.
Results For every 1000 women screened over 10 years,
167-251 (depending on age) receive an abnormal result; 56-64
of these women undergo at least one biopsy, 9-26 have an
invasive cancer detected by screening, and 3-6 have ductal
carcinoma in situ (DCIS) detected by screening. More breast
cancers (both invasive and DCIS) are diagnosed among
screened than unscreened women. For example, among 1000
women aged 50 who have five biennial screens, 33 breast
cancers are diagnosed: 28 invasive cancers (18 detected at
screening and 10 interval cancers) and five DCIS (all detected at
screening). By comparison, among 1000 women aged 50 who
decline screening, 20 cancers are diagnosed over 10 years.
There are about 0.5, 2, 3, and 2 fewer deaths from breast cancer
over 10 years per 1000 women aged 40, 50, 60, and 70,
respectively, who choose to be screened compared with women
who decline screening at times determined by relevant policy.
Conclusion Benefits and harms of screening mammography
are relatively finely balanced. Quantitative estimates such as
these can be used to support individual informed choices about
screening.
Introduction
Screening mammography is recommended for women aged
50-69 on the evidence that benefits outweigh harms.1 2 The issue
remains controversial, however, especially for women outside
this age group. According to the General Medical Council,3 the
UK National Screening Committee,4 and others5 comprehensive
information about screening should be available to support
informed choices. General principles on the provision of
information about cancer screening include that information
should be balanced (describing benefits and harms over a similar
time frame, such as 10 years) and that estimates should be
presented with a constant denominator (such as per 100 or 1000
people).6 Important harms include anxiety, which can be long
lasting, generated by false positive results,7 and the psychological
and physical impact of detection and treatment of disease that
would not have been diagnosed without screening (overdetec-
tion or detection of inconsequential disease).8
We developed a model of screening mammography for
women aged 40 to 79. We constructed it so that outcomes are
presented per 1000 women of ages 40, 50, 60 and 70 years who
choose to be screened at times relevant to policy. Biennial
screening mammography (using two view mammography and
double reading of films) has been provided in Australia for more
than a decade, targeting women aged 50-69 by advertising and
letters of invitation.1 Women aged 40-49 and those aged 70-79
may also be screened in the programme. Thus the major
decision points for women are at age 40, when they can choose
to begin screening or not; at age 50, when they will be invited to
screening up to the age of 69; and at age 70, when they may
choose to continue or cease screening.
Clearly, women can make additional choices at any time to
drop in or out of screening, but these are the common decision
points under existing policy.
Methods
We constructed a Markov process model for two hypothetical
cohorts. In one cohort women undergo biennial screening over
10 years and in the other cohort they do not (table 1). The model
is based on 100% participation in the screening cohort and no
participation in the non-screening cohort and thus generates the
consequences for women who attend screening regularly versus
those who decline it. The first scenario compares women who
start screening at age 40 with women who decline screening at
age 40 (to estimate the effect of starting screening early). The
second and third scenarios model outcomes for women who
choose to start screening at age 50 and then continue over the
full life of the screening programme—that is, from 50-69 years.
As this decision will hold for 20 years, the second scenario pro-
vides outcomes for the first 10 years, and the third scenario pro-
vides outcomes for the second 10 years of this choice. The last
scenario compares outcomes among women aged 70 who have
been screened regularly and then choose to continue screening
for another 10 years with women who stop screening at 69 years
(to estimate the effect of extending screening to 79 years).
Data sources and assumptions
The box summarises data sources and assumptions underlying
the model.
Incidence of breast cancer in screened women and other
immediate outcomes of screening
We used data from BreastScreen Australia9–13 to populate the
model. These data comprise outcome information for screening
The formula used to calculate mortality from breast cancer in unscreened
women is on bmj.com
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and subsequent tests for more than 1.25 million women
screened each year. To minimise variation from year to year, we
pooled the most recent five years (1997-2001) of data. For each
screen, we obtained the numbers of breast cancers detected
(invasive and ductal carcinoma in situ, DCIS), women recalled for
extra imaging and biopsy, and interval cancers (0-12 months and
12-24 months) after a screen.
Incidence of breast cancer in unscreened women
We used the model developed by Taylor and Boyages for the age
specific incidence of breast cancer in unscreened women.14 We
estimated age specific incidence for DCIS by assuming that 2%
of breast cancer diagnosed clinically in unscreened women is
DCIS, on the basis of rates of DCIS reported before screening.15
Mortality from breast cancer in unscreened women
We used data on mortality from breast cancer for the five most
recent years of national data from Australian Institute of Health
and Welfare.9 10 As these data include both women who did and
did not undergo screening, we adjusted them using age specific
screening participation rates over the same time period9 10 to
obtain mortality for unscreened women (see appendix on
bmj.com).
Mortality from breast cancer in screened women
Among 50-69 year old women, screening mammography
reduces the risk of death from breast cancer by about 25%.16 17 As
this figure is attenuated by non-compliance, we used a relative
risk reduction of 37% (95% confidence interval 21% to 49%),17
which includes adjustment for full participation to represent the
effect for women who actually attend screening. We used the
same relative risk reduction for women > 70. In sensitivity analy-
ses, we tested the effect of varying the relative risk reduction over
the approximate range of the 95% confidence interval reported
by Glasziou (20% to 50%).17 For women aged 40-49 screening
mammography may reduce mortality from breast cancer by
15%; we used a reduction of 23%, adjusted for compliance.18
As the benefit of screening on mortality is not immediate we
assumed that such benefit accumulates linearly over five years
from the start of screening, and, similarly, we assumed that the
benefit declines linearly over the five years after screening ceases.
We applied the relative risk reductions to the age specific
mortality from breast cancer for unscreened women to derive
the rates for screened women.
Mortality due to causes other than breast cancer
We used data from the Australian Bureau of Statistics for age
specific all cause mortality. These rates were split into mortality
from breast cancer and from causes other than breast cancer.
Rates for causes other than breast cancer for screened and
unscreened women were fixed at the age specific rate for
unscreened women. We applied these rates to the cohort at risk
in each given year to calculate the number of deaths from causes
other than breast cancer in screened and unscreened women. All
rates were converted to annual probabilities.
All cause mortality
We calculated the total number of deaths in each year by
summing the number of deaths due to breast cancer with the
number of deaths due to causes other than breast cancer.
Progression through the model
Each scenario begins with a defined number of women (1000) at
a specified starting age. We then apply age specific probabilities
to reflect the likely transition of the cohorts through 10 one year
cycles.
Effect of comorbidity
We also estimated the impact of comorbidity on outcomes as
participants in excellent health can expect to gain more from
screening, particularly at older ages when competing causes of
death increase. We used estimates for mortality according to self
reported health status in four categories (excellent, good, fair, or
poor).19 Using the combined category of good or fair health as
the base case, we compared outcomes for women in poor health
and for women in excellent health by using rates for women
seven years older or five years younger.19
Results
Outcomes of screening over 10 years for women aged 40, 50,
60, and 70
Table 2 shows results for all age groups. Using 50 year old
women as an example for interpretation, among 1000 women
aged 50 who are screened biennially over the next 10 years, 242
will receive an abnormal result and be recalled for assessment.
Of these, 178 will have only more imaging and 64 will undergo
biopsy. Therefore, over 10 years there is a 24% chance of being
recalled and a 6% chance of having at least one breast biopsy. A
total of 23 cancers will be detected by screening (18 invasive and
Table 1 Modelled scenarios of effect of screening mammography
Screening strategy Comparator
1000 women who begin screening at age 40
and have five biennial screens (from 40-49
years)
No screening over same time period (that is,
from ages 40-49)
1000 women who begin screening at age 50
and have five biennial screens (from 50-59
years)
No screening over same time period (that is,
from ages 50-59, having also previously
declined screening at 40)
1000 women aged 60, who now have a
further five biennial screens (from 60-69
years) having been screened biennially
from 50
No screening over same time period (that is,
from 60-69 years, having also previously
declined screening at 40 and 50)
1000 women aged 70, who now have a
further five biennial screens (from 70-79
years) having been screened biennially
from 50
Stop at 69, having previously been screened
from 50-69 years
Data sources and assumptions
Data (from BreastScreen Australia unless stated otherwise)
Participation in screening9 10
Invasive breast cancer detected by screening9 10
Ductal carcinoma in situ (DCIS) detected by screening9 10
Recall rates9 10
Type of recall procedure11–13
Interval cancer rate (0-12 and 13-24 months)9 10
Overall incidence of and mortality from breast cancer 9 10
Incidence of breast cancer in unscreened women (model by
Taylor and Boyages14)
Mortality from all causes (Australian Bureau of Statistics age
specific mortality 2001)
Assumptions
Incidence of DCIS in unscreened women (assumed to be 2% of
total incidence of breast cancer in unscreened women15)
Size of benefit on breast cancer mortality due to screening
(relative risk reduction of 37% for women aged 50-7916 17 and
23% for women 40-4917 18)
Onset and duration of benefit on breast cancer mortality (benefit
accrues linearly to maximal level over first five years after starting
screening; benefit declines linearly to nothing over five years after
stopping screening)
Mortality from causes other than breast cancer (screened and
unscreened women experience the same risk of death from
causes other than breast cancer)
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five DCIS). A further 10 interval cancers will be diagnosed, giving
a total of 33 cancers diagnosed in the screening group. In com-
parison, among 1000 women aged 50 who decline screening,
over 10 years about 20 breast cancers (almost all of which are
invasive) will be detected. Among the screened women four will
die from breast cancer compared with six among the unscreened
women; this is in the context of around 31 deaths from all causes
in the unscreened group and 29 deaths from all causes (includ-
ing breast cancer) in the screened group.
Similar interpretations apply to the other scenarios. The gen-
eral pattern is the same for women who choose or decline
screening at 40, although the numbers of diagnoses of breast
cancer, deaths from breast cancer, and deaths from all causes are
lower. For women aged 60 the pattern is again similar but with
larger numbers of diagnoses, deaths from breast cancer, and
deaths from all causes.
For women who continue screening into their 70s, over 10
years two fewer women per thousand die from breast cancer
than in women who stop screening (six v eight deaths from
breast cancer). The number of diagnoses of breast cancer in
screened women is about 41 and the number in unscreened
women about 26. All cause mortality is substantially higher than
in younger women, reflecting the increase in deaths from other
causes.
Sensitivity analyses that varied the relative risk reductions for
women over 50 across the range of 20-50% resulted in only small
changes in the absolute number of deaths related to breast can-
cer for each age group. With a relative risk reduction of 50%, the
number of deaths from breast cancer in screened women
decreased from 4.0 to 3.7 for 50 year olds; from 5.1 to 4.5 for 60
year olds; and from 6.2 to 5.1 for 70 year old women. Full details
of the sensitivity analysis are available on request.
Effect of self reported health status
Self reported health status had little effect on incidence of or
mortality from breast cancer, but, as expected, had a striking
effect on the mortality from causes other than breast cancer.
Table 3 shows data for women aged 70; other results from this
analysis are available on request.
Discussion
We have presented easy to use, age specific estimates of the ben-
efits and harms of screening mammography. These estimates
should give women, clinicians, and service providers full
information about mammography screening. In summary, for
every 1000 women screened over 10 years, 167-251 (depending
on age) receive an abnormal result and are recalled; about 56-64
of these have at least one biopsy. Nine to 26 women (depending
on age) have an invasive cancer detected by screening and three
to six have DCIS detected by screening. About 0.5, 2, 3, and 2
fewer deaths from breast cancer occur over 10 years among 1000
women aged 40, 50, 60, and 70 years respectively who choose to
be screened compared with women who decline screening at
these times.
Strengths and limitations
Although other models of mammographic screening exist, this is
the first comprehensive use of a balance sheet approach.
Furthermore our model is unique in modelling screening
outcomes cumulatively over 10 years (five screening rounds) for
specific age groups of women, at decision points relevant to
policy. We have also considered the potential impact of
comorbidity on the outcomes of screening.
There is uncertainty around the reductions in mortality
attributable to screening mammography,2 16–17 especially for
women in their 40s and 70s. As the relative risk reduction in
women 65-74 is similar to that observed in women aged 50-6420
we used the same estimate of effect for women aged 50-79.
Screening mammography, however, may be more effective now
than it was at the time of the randomised trials so we conducted
a sensitivity analysis using a larger relative risk reduction of 50%
for women > 50. This makes little difference to the balance of
benefit and harms.
Table 2 Outcomes for women who undergo screening compared with those who do not. Figures are cumulative number out of 1000 women over 10 years
Event over 10 years
Age 40 Age 50 Age 60 Age 70
Begin screening at
age 40, five biennial
screens No screening
Begin screening at
age 50, five biennial
screens No screening
Have five more












191.4 177.9 128.6 110.2
Biopsy (total having at
least one biopsy)
59.5 64.1 56.0 56.4
Fine needle aspiration
biopsy
31.7 30.5 25.4 25.4
Core biopsy 21.7 27.2 25.3 25.8
Open biopsy 6.1 6.4 5.3 5.2
Invasive breast cancer
detected at screening
8.5 17.6 23.3 26.4
Develop interval cancer 9.1 10.4 9.2 8.8
Diagnosis of invasive
breast cancer
17.6 13.2 28.1 19.8 32.5 23.9 35.1 25.1
DCIS* 3.4 0.3 4.9 0.4 5.5 0.5 5.7 0.5
Breast cancer diagnosis of
any kind
21.0 13.5 32.9 20.2 38.0 24.4 40.8 25.6
Die from breast cancer 2.0 2.5 4.0 5.9 5.1 8.1 6.2 8.4
Die from causes other
than breast cancer
10.8 10.8 25.3 25.2 68.5 68.4 199.5 199.3
Total who die 12.8 13.3 29.3 31.1 73.6 76.5 205.7 207.8
*Ductal carcinoma in situ, detected by screening in screening group, and presenting clinically with symptoms in unscreened group.
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Overdetection and overtreatment are important but under-
appreciated harms of screening.8 Increased numbers of breast
cancers are diagnosed at all ages in women who choose screen-
ing. Some of this is due to increased detection of DCIS by
screening and this is explicit in the model. DCIS is a non-invasive
form of cancer that may or may not progress to invasive cancer.
It is associated with low mortality after surgical treatment and the
value of its early detection and treatment is uncertain.21
Diagnosis of invasive cancer is more common among
screened women, due to lead time (earlier diagnosis generates a
mortality benefit) and detection of invasive breast cancer, which,
in the absence of screening, would not have been diagnosed
within the remainder of the woman’s lifetime (overdetection). We
do not know how much of the increased detection is lead time
and how much is overdetection; published estimates of the over-
detection range from 2% to 30%.22–24 Further work is required to
clarify the extent of overdetection within breast screening. This is
important because the effects of overdetection extend beyond
living with the diagnosis of cancer and include adverse effects of
treatment for breast cancer (surgery, endocrine therapy, chemo-
therapy, radiotherapy).
Because screening is well established in Australia, the
incidence and mortality of breast cancer in the absence of
screening cannot be directly measured and thus we used
modelled estimates of incidence14 and estimated mortality (see
appendix on bmj.com). We compared these estimates with Aus-
tralian incidence and mortality statistics from before the
widespread availability of mammographic screening and found
that they were similar. In addition, we validated our model by
comparing the 10 year incidence of breast cancer weighted for
participation in screening generated by the model with the 10
year incidence of breast cancer from published national
estimates.
Interpretation and implications for future practice and
research
The information presented here is readily usable by women con-
sidering screening mammography. In essence the decision to be
screened is a gamble; there is only a small chance of benefit but
the stakes are high. Some women will be happy to choose the
gamble even though they may experience anxiety, inconven-
ience, and physical adverse effects; other women will not.
Clinicians may be able to use this information to support discus-
sions with women about these possibilities and to support their
patients in making a choice that is consistent with their own cir-
cumstances and values and preferences. As well as providing
information for women aged 50-69 years, it may be useful for cli-
nicians’ discussions with patients in “out of target” age groups by
making explicit the possible risks and benefits of a decision to be
screened. We have incorporated these estimates into decision
aids that are currently being tested in Australia. These methods
can be applied to different populations and other screening con-
texts. The effect of such information on decision quality and
screening participation is currently unknown but can be tested.
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What is already known on this topic
Outcomes of screening mammography include benefits
(reduced risk of death from breast cancer) and harms
(physical and psychological adverse effects from screening
and follow-up tests and detection of inconsequential
disease)
Current information about screening mammography fails
to meet women’s needs for full and balanced information
about these benefits and harms
What this study adds
This model of screening mammography presents
quantitative information about the outcomes of screening
in a form suitable to inform decisions about screening
It provides information about cumulative benefits and
harms over the same time frame (10 years) for women aged
40, 50, 60, and 70 years who are considering screening
Papers
BMJ Online First bmj.com page 5 of 5
